HK1209057A1 - Methods of treating overweight and obesity - Google Patents

Methods of treating overweight and obesity

Info

Publication number
HK1209057A1
HK1209057A1 HK15109846.0A HK15109846A HK1209057A1 HK 1209057 A1 HK1209057 A1 HK 1209057A1 HK 15109846 A HK15109846 A HK 15109846A HK 1209057 A1 HK1209057 A1 HK 1209057A1
Authority
HK
Hong Kong
Prior art keywords
obesity
methods
treating overweight
overweight
treating
Prior art date
Application number
HK15109846.0A
Other languages
English (en)
Chinese (zh)
Inventor
Preston Klassen
Kristin Taylor
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of HK1209057A1 publication Critical patent/HK1209057A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01G—WEIGHING
    • G01G19/00—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups
    • G01G19/40—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight
    • G01G19/413—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight using electromechanical or electronic computing means
    • G01G19/414—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight using electromechanical or electronic computing means using electronic computing means only
    • G01G19/4146—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight using electromechanical or electronic computing means using electronic computing means only for controlling caloric intake, e.g. diet control
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • G09B19/0092—Nutrition
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B5/00—Electrically-operated educational appliances
    • G09B5/06—Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
    • G09B5/065—Combinations of audio and video presentations, e.g. videotapes, videodiscs, television systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Theoretical Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mathematical Physics (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Nutrition Science (AREA)
  • Multimedia (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15109846.0A 2012-06-06 2015-10-08 Methods of treating overweight and obesity HK1209057A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656451P 2012-06-06 2012-06-06
PCT/US2013/044368 WO2013184837A1 (en) 2012-06-06 2013-06-05 Methods of treating overweight and obesity

Publications (1)

Publication Number Publication Date
HK1209057A1 true HK1209057A1 (en) 2016-03-24

Family

ID=49712605

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109846.0A HK1209057A1 (en) 2012-06-06 2015-10-08 Methods of treating overweight and obesity

Country Status (33)

Country Link
US (4) US9633575B2 (ja)
EP (3) EP2858640B1 (ja)
JP (4) JP2015518897A (ja)
KR (5) KR20150016405A (ja)
CN (2) CN104470512A (ja)
AR (2) AR093694A1 (ja)
AU (2) AU2013271622B2 (ja)
BR (1) BR112014030282A2 (ja)
CA (1) CA2875056C (ja)
CL (1) CL2014003329A1 (ja)
CO (1) CO7240377A2 (ja)
CY (1) CY1123183T1 (ja)
DK (2) DK2858640T3 (ja)
EA (1) EA201492175A1 (ja)
EC (1) ECSP15000223A (ja)
ES (2) ES2802048T3 (ja)
GT (1) GT201400278A (ja)
HK (1) HK1209057A1 (ja)
HU (2) HUE049859T2 (ja)
IL (3) IL300868A (ja)
IN (1) IN2015DN00042A (ja)
JO (1) JOP20130346B1 (ja)
LT (2) LT2858640T (ja)
MA (1) MA37714A1 (ja)
MX (4) MX369990B (ja)
NI (1) NI201400144A (ja)
PE (1) PE20150358A1 (ja)
PL (2) PL3730132T3 (ja)
PT (2) PT2858640T (ja)
RS (2) RS60682B1 (ja)
TN (1) TN2014000508A1 (ja)
TW (1) TW201904575A (ja)
WO (1) WO2013184837A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2303085T3 (es) 2003-04-29 2008-08-01 Orexigen Therapeutics, Inc. Composiciones que afectan a la perdida de peso.
BRPI0618918B8 (pt) 2005-11-22 2021-05-25 Nalpropion Pharmaceuticals Llc uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US10332053B2 (en) * 2013-02-13 2019-06-25 Tutsho, Llc Food data access and delivery system
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10638786B2 (en) * 2017-08-16 2020-05-05 Zolighter, LLC Methods of reducing visceral fat and related compositions
US11007121B2 (en) * 2018-02-15 2021-05-18 Robin ARORA Systems, methods and apparatus for substance dependence cessation management
RU2706385C1 (ru) * 2019-01-09 2019-11-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения больных метаболическим синдромом
EP4062421A4 (en) * 2019-11-18 2023-12-13 Mandometer AB DIAGNOSIS OF EATING DISORDERS

Family Cites Families (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3942641A (en) 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4089855A (en) 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
US4218433A (en) 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
ZA824382B (en) 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
JPS58134019A (ja) 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4895845A (en) 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
NL8800823A (nl) 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
PH23901A (en) 1987-05-04 1989-12-18 Lilly Co Eli Treatment of diabetes using fluoxetine
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
EP0483152A4 (en) 1989-05-09 1992-12-02 Whitby Research Incorporated A method of reducing body weight and food intake using a dopamine d2 receptor agonist
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
ES2062310T3 (es) 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
FR2657350B1 (fr) 1990-01-19 1992-05-15 Centre Nat Rech Scient Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
DE69525847T2 (de) 1994-09-19 2002-09-05 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US6221399B1 (en) 1995-08-17 2001-04-24 Csir Method of making controlled release particles of complexed polymers
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
EP0914097B1 (en) 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
EP0934069B1 (en) 1996-05-07 2006-11-08 Pliva-Istrazivanje I Razvoj D.D.O. Method and composition for the treatment of lipid and glucose metabolism disorders
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
UA53655C2 (uk) 1996-06-28 2003-02-17 Орто-Макнейл Фармасьютікел, Інк. Спосіб лікування ожиріння
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
AU8699298A (en) 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
DE69811378T2 (de) 1997-10-03 2004-02-12 Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
WO1999033465A1 (en) 1997-12-26 1999-07-08 Dainippon Pharmaceutical Co., Ltd. Remedy for neurodegenerative diseases___________________________
EP1829544A1 (en) 1998-01-21 2007-09-05 Glaxo Group Limited Pharmaceutically active morpholinol
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030035840A1 (en) 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
EP1187603B1 (en) 1999-06-14 2007-08-08 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
JP2003509349A (ja) 1999-09-15 2003-03-11 エラン ファーマシューティカルズ，インコーポレイテッド ヘテロアリールメタンスルホンアミドを使用するニューロパシー性疼痛を処置するための方法。
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
EP1220673A2 (en) 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
US20030144271A1 (en) 2000-01-22 2003-07-31 Albert Shulman Methods for the treatment of substance abuse
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US20020090615A1 (en) 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1299104B1 (en) 2000-02-08 2009-05-13 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20010049375A1 (en) 2000-03-15 2001-12-06 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
ES2425114T3 (es) 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
AU5066101A (en) 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU2001250646A1 (en) 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
MXPA03001001A (es) 2000-08-02 2003-10-14 Johnson & Johnson Derivados anticonvulsionantes utiles para el tratameinto de la depresion.
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
RU2197250C2 (ru) 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
PT1333887E (pt) 2000-10-30 2006-10-31 Ortho Mcneil Pharm Inc Metodo de tratamento de desordens musculares
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CA2445528A1 (en) 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
US6462237B1 (en) 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
MXPA04001208A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Composiciones y metodos para evitar el abuso de los opioides.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
CA2457361C (en) 2001-08-06 2008-11-04 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030044462A1 (en) 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
ITFI20010230A1 (it) 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
MXPA04006163A (es) 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
PL371596A1 (en) 2002-05-17 2005-06-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
WO2004006959A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
AU2003253925A1 (en) 2002-07-18 2004-02-09 Banyu Pharmaceutical Co., Ltd. Combination therapy for the treatment of obesity
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
WO2005000265A2 (en) 2002-09-11 2005-01-06 Elan Pharma International Ltd. Gel-stabilized nanoparticulate active agent compositions
AU2003283958A1 (en) 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
CA2500908A1 (en) 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
PL377351A1 (pl) 2002-12-13 2006-01-23 Cilag Ag Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
CA2414500A1 (en) 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US7332183B2 (en) 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
US20040158194A1 (en) 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
EP1772147A2 (en) 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
EP1613333A1 (en) 2003-04-04 2006-01-11 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
WO2004091593A2 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
ES2303085T3 (es) 2003-04-29 2008-08-01 Orexigen Therapeutics, Inc. Composiciones que afectan a la perdida de peso.
CA2525323A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
EP1633400A2 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1663179A1 (en) 2003-07-21 2006-06-07 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
WO2005009377A2 (en) 2003-07-23 2005-02-03 University Of Kentucky Research Foundation Novel oral bioavailable prodrugs
WO2005016310A1 (en) 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
RS51934B (en) 2003-08-08 2012-02-29 Biovail Laboratories International Srl. BUPROPION HYDROCHLORIDE TABLE WITH MODIFIED RELEASE
US20050043704A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043773A1 (en) 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
WO2005018652A1 (en) 2003-08-21 2005-03-03 Duchesnay Inc. Micronutrient supplement
US20050043705A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
ATE464049T1 (de) 2003-09-25 2010-04-15 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
US20050112198A1 (en) 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005049043A1 (en) 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
US20050232990A1 (en) 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20060160750A1 (en) 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
WO2005079773A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
SE0400378D0 (sv) 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20050214371A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2005107806A1 (en) 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
JP2007536229A (ja) 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
CA2576505A1 (en) 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss
DE602005020462D1 (de) 2004-08-25 2010-05-20 Essentialis Inc Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
AU2005286733B2 (en) 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2005302669A1 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as CB1 antagonists
EP1807390A4 (en) 2004-11-04 2008-07-02 Neurogen Corp ARYL ALKYL UREA AS CB1 ANTAGONISTS
US20060122127A1 (en) 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
JP2006232675A (ja) 2005-02-22 2006-09-07 Kowa Co 複合型口腔内溶解用固形製剤
WO2006113704A2 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US20060246131A1 (en) 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications
CN101208092A (zh) 2005-05-31 2008-06-25 奥雷西根治疗公司 用于处理精神障碍的方法和组合物
WO2007012064A2 (en) 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
CN101237886A (zh) 2005-07-27 2008-08-06 奥雷西根治疗公司 产生重量减轻的组合物
PL3524261T3 (pl) 2005-08-19 2024-04-15 Amylin Pharmaceuticals, Llc Eksendyna do stosowania w leczeniu cukrzycy i zmniejszania masy ciała
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
BRPI0618918B8 (pt) 2005-11-22 2021-05-25 Nalpropion Pharmaceuticals Llc uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
WO2007062228A1 (en) 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
WO2007084290A2 (en) 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2007145863A2 (en) * 2006-06-05 2007-12-21 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
RU2342195C1 (ru) 2007-04-18 2008-12-27 Институт проблем комплексного освоения недр РАН Устройство для механоактивации сульфидсодержащих минеральных продуктов
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
AU2011203867B2 (en) * 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
WO2012070043A1 (en) 2010-11-26 2012-05-31 Ramot At Tel-Aviv University Ltd. Method and composition for weight-gain management
EP3222280B1 (en) 2010-12-03 2021-01-20 Nalpropion Pharmaceuticals LLC Increasing drug bioavailability in naltrexone therapy
LT2646011T (lt) 2010-12-03 2017-11-10 Orexigen Therapeutics, Inc. Besaikio valgymo arba neįveikiamo potraukio valgyti sumažinimo būdai
EP2858640B1 (en) * 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
EP4104824A1 (en) 2022-12-21
AU2013271622A1 (en) 2015-01-22
BR112014030282A2 (pt) 2017-06-27
EP2858640A4 (en) 2016-01-20
KR20210012056A (ko) 2021-02-02
US11139056B2 (en) 2021-10-05
GT201400278A (es) 2017-08-01
MX369990B (es) 2019-11-27
US9633575B2 (en) 2017-04-25
JOP20130346B1 (ar) 2022-03-14
CY1123183T1 (el) 2021-10-29
IL300868A (en) 2023-04-01
ES2802048T3 (es) 2021-01-15
TN2014000508A1 (en) 2016-03-30
KR20200035501A (ko) 2020-04-03
MA37714A1 (fr) 2017-12-29
TW201904575A (zh) 2019-02-01
US10403170B2 (en) 2019-09-03
DK2858640T3 (da) 2020-06-29
CL2014003329A1 (es) 2015-04-06
JP2023086769A (ja) 2023-06-22
MX2019008217A (es) 2019-09-13
CA2875056A1 (en) 2013-12-12
HUE059651T2 (hu) 2022-12-28
EP3730132B1 (en) 2022-05-04
IN2015DN00042A (ja) 2015-05-22
JP2021080274A (ja) 2021-05-27
JP2018158945A (ja) 2018-10-11
EP2858640A1 (en) 2015-04-15
US20220208327A1 (en) 2022-06-30
EP2858640B1 (en) 2020-03-25
JP2015518897A (ja) 2015-07-06
NI201400144A (es) 2015-07-15
PT3730132T (pt) 2022-08-16
RS63569B1 (sr) 2022-10-31
CO7240377A2 (es) 2015-04-17
KR20220042241A (ko) 2022-04-04
RS60682B1 (sr) 2020-09-30
JP6878360B2 (ja) 2021-05-26
ECSP15000223A (es) 2015-09-30
KR20230010811A (ko) 2023-01-19
IL235939A0 (en) 2015-01-29
AR093694A1 (es) 2015-06-17
LT2858640T (lt) 2020-08-10
IL282128A (en) 2021-05-31
WO2013184837A1 (en) 2013-12-12
ES2924024T3 (es) 2022-10-04
CN110893181A (zh) 2020-03-20
US20170221380A1 (en) 2017-08-03
CA2875056C (en) 2024-03-26
PL2858640T3 (pl) 2020-10-05
MX2019011209A (es) 2019-11-01
AU2018203271A1 (en) 2018-05-31
AU2013271622B2 (en) 2018-03-01
AR125234A2 (es) 2023-06-28
DK3730132T3 (da) 2022-08-08
PE20150358A1 (es) 2015-04-06
HUE049859T2 (hu) 2020-10-28
MX2014014822A (es) 2015-05-11
EP3730132A1 (en) 2020-10-28
KR20150016405A (ko) 2015-02-11
PT2858640T (pt) 2020-06-30
MX2022005401A (es) 2022-05-25
CN104470512A (zh) 2015-03-25
US20150154883A1 (en) 2015-06-04
PL3730132T3 (pl) 2022-10-10
LT3730132T (lt) 2022-08-25
US20200098285A1 (en) 2020-03-26
EA201492175A1 (ru) 2015-10-30

Similar Documents

Publication Publication Date Title
IL282128A (en) Methods for treating overweight and obesity
PT2898061T (pt) Composições probióticas para o tratamento da obesidade e de condições relacionadas com a obesidade
HK1212239A1 (en) Methods for prevention and treatment of preeclampsia
EP2774616A4 (en) APPLICATION OF ROSEBURIA IN THE TREATMENT AND PREVENTION OF OBESITY-RELATED DISEASES
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2675460A4 (en) TREATMENT OF FAT TISSUE UNDER CHIN
HK1200348A1 (en) Methods and materials for treatment of pompes disease
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
GB201217296D0 (en) Method of treatment and/or prevention
HK1214355A1 (zh) 用於治療和/或限制糖尿病發展的方法
IL232135A0 (en) Therapeutic combinations and methods for treating melanoma
EP2804614A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND / OR ADIPOSITAS
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
SG10201510568WA (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
HK1212554A1 (zh) 給予利福昔明用於重量減輕和肥胖治療的方法
EP2654763A4 (en) USE OF MARIHUANA AND COMPOUNDS CONTAINED IN THE TREATMENT OF ADIPOSITAS
ZA201304381B (en) Novel-19-nor-steroid and their use for treating progesterone-dependent conditions
EP2844219A4 (en) SENSITIZING COMPOSITION AND METHOD OF USE
EP2709730A4 (en) TREATMENT AND PROGNOSIS OF CANCER
HK1208159A1 (en) Sorcs1 for use in the treatment of obesity and overweight sorcs1
GB201213968D0 (en) Prevention and treatment of osteoarthritis
GB201113140D0 (en) Prediction and treatment of cancer
ZA201501068B (en) Methods for prevention and treatment of preeclampsia
GB201222855D0 (en) Lock Means and Method of Use Thereof
GB201203663D0 (en) Note pad and method of use thereof